Inactive Instrument

LogicBio Therapeutics, Inc. Stock price

Equities

LOGC

US54142F1021

Pharmaceuticals

Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 57 16-03-31
Chief Tech/Sci/R&D Officer - 19-03-31
Chief Tech/Sci/R&D Officer - 19-01-31
Members of the board TitleAgeSince
Chief Executive Officer 57 16-03-31
More insiders
LogicBio Therapeutics, Inc. is a clinical-stage genetic medicine company. It is focused on genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. Its genome editing platform, GeneRide, is an approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid repair process, potentially to durable therapeutic protein expression levels. Its gene delivery platform, sAAVy, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate, LB-001, for the treatment of methylmalonic acidemia (MMA) in pediatric patients. LB-001 is designed to introduce a functional copy of the methylmalonyl-CoA mutase (MUT) gene into the genome of MMA patients. It is developing LB-401 for the treatment of hereditary tyrosinemia type 1 (HT1). The Company is developing LB-301 for the treatment of Crigler-Najjar syndrome (CN).
More about the company
  1. Stock
  2. Equities
  3. Stock LogicBio Therapeutics, Inc. - Nasdaq